Full history for every metric is available with a Kvantra account
CinCor Pharma, Inc. (CINC)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 0 | 0 | 0 | 0 |
| Operating profit | $m | -43 | -83 | |||||
| Net profit | $m | - | - | - | -5 | -22 | -50 | -93 |
| EPS reported | $ | -1.42 | -2.55 | |||||
| Operating cashflow per share | $ | -0.87 | -0.87 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.87 | -0.87 | |||||
| Free cash flow | $m | -31 | -63 | |||||
| Net debt | $m | -137 | -522 | |||||
| Book value equity | $m | -64 | - | |||||
| Book value per share | $ | -1.80 | - | |||||
| Number of shares | m | 35.42 | 40.81 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -8.89 | -16.15 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -18.37 | -20.04 | |||||
| EV/EBITDA LTM | x | -12.42 | -8.91 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -8.88% | -4.89% | |||||
| FCF Yield | % | -5.44% | -4.99% | |||||
| Quality | ||||||||
| ROE | % | 79.02% | 110.68% | |||||
| ROIC | % | -34.11% | -34.11% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 3.94 | 3.94 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -24.11% | -41.08% | |||||
| Net debt/Equity | x | 2.14 | - | |||||
| Gross debt/equity | x | -0.00 | - | |||||
Company overview
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CinCor Pharma, Inc. (CINC)
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free